ROIV Roivant Sciences Ltd.
Company Analysis
Latest News
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
The U.S. Food and Drug Administration (FDA) approved LISRAYA (brepocitinib) for adults with dermatomyositis. Roivant Sciences' subsidiary, Priovant...
Roivant's Brepocitinib Clears Skin in Phase 3, Targeting 2026 FDA Approval
Priovant Therapeutics, a Roivant Sciences subsidiary, published skin-specific Phase 3 VALOR trial results for brepocitinib in JAMA Dermatology. The study...
Roivant's 7% Pop on a Narrower Loss and a Drug Launch Six Weeks Away — Is the Market Pricing in a Future That Hasn't Arrived?
Shares shifted as Roivant Sciences surged 7.2% to $38.80, a delayed reaction to first-quarter results reported August 6 and growing anticipation around a...
🟢 Roivant Sciences is trading 7% up in pre-market after narrower first-quarter loss
Roivant Sciences is trading 7.18% up now at $38.80 after investors reacted favorably to its narrower first-quarter loss despite weaker revenue. - August 6...
Roivant's first quarter EPS beats estimates on lower-than-expected loss, while its cash position remains strong at $3.9B.
Roivant Sciences reported a first quarter net loss of $0.26 per share, narrower than analyst expectations, on revenue of $1.4 million which missed estimates....
Roivant Sciences Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Roivant Sciences is projected to report a Q2 2026 revenue of approximately $2.00 million and a consensus EPS loss of -$0.45, while its current stock price of...
🟢 Roivant Sciences is trading 4.1% up today amid a broad biotech rally and risk-on sentiment
Roivant Sciences is trading 4.1% up at $34.68, outperforming recent sessions as a strong risk-on mood lifts the broader biotech sector. • The move follows...
🟢 Roivant Sciences is trading 4.2% up today amid a broad tech-led market rebound
Roivant Sciences is trading 4.2% up today at $34.27 amid a broad U.S. equity rebound led by technology stocks. • The move aligns with a wider market rally,...
🟢 Roivant Sciences is trading 4.9% up today after Q4 earnings beat and $770M Moderna settlement gain
Roivant Sciences is trading at $36.20 (+4.91%) in pre-market action after fiscal Q4 2026 results significantly beat analyst expectations due to a major...
Roivant's Genevant Sues Pfizer Globally, Escalating Multi-Billion Dollar Patent Fight
Roivant Sciences' subsidiary Genevant Sciences and Arbutus Biopharma filed three new patent infringement lawsuits against Pfizer and BioNTech. These filings in...
🔴 Roivant Sciences is trading 4.1% down today on sector-wide profit-taking
Roivant Sciences is trading 4.1% down at $34.51 as the broader biotech sector pulls back and investors take profits following a sharp rally. • The decline...
🔴 Roivant Sciences is trading 4.1% down today after a multi-week rally fueled by deal-related cash and index flows
Roivant Sciences is trading 4.1% down today at $35.29 as the stock pulls back following a multi-week rally fueled by deal-related cash inflows and index-driven...
🟢 Roivant Sciences is trading 4.7% up today amid continued biotech momentum
Roivant Sciences is trading at $38.55 (+4.7%) in after-hours as the stock extends its multi-week uptrend amid positive sentiment toward its biotech...
Roivant Sciences Director Sells $56 Million in Shares, Retains Large Stake
Roivant Sciences Director Keith S. Manchester sold over $56.4 million in company stock according to filings reported on July 1, 2026. The transactions...
Roivant President Sells $34M in Stock Following Index Removal
Roivant Sciences President and Chief Investment Officer Mayukh Sukhatme sold 1,000,000 shares on June 30, 2026. The total transaction value reached...
🟢 ROIV extends move to 5.0% up
ROIV is trading at $33.83, up 5.0% versus the comparison close of $32.21 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 ROIV is trading 4.24% up today following Moderna settlement and positive pipeline updates
ROIV is trading at $33.58 (4.24% up) following a strong follow-through from the prior session and continued optimism around recent company developments. •...
🟢 Roivant Sciences Ltd is trading 4% up today on improved risk sentiment
Roivant Sciences Ltd is trading 4% up today at $29.55 on improved risk sentiment, tracking broader gains across major U.S. indices. • The advance occurs on...
Roivant Secures $950M Moderna Settlement, Eyes Major 2026 Clinical Data
Roivant Sciences expects a $950 million upfront payment from Moderna in July 2026. This payment is part of a $2.25 billion global settlement resolving patent...